WHITE PAPER
Perspectives on the Availability of Innovative Medicines
Building on the Patients W.A.I.T. indicator
Jul 30, 2021

Improving the availability of medicines authorised in the European Union (EU) is a key priority for all stakeholders in healthcare. Recent studies such as the EFPIA Patients WA.I.T. indicator which is completed yearly and supported by IQVIA, serves as a foundation and evidence-base for an informed discussion on the root causes of unavailability and delay to accessing innovative medicines.

Throughout this report, IQVIA explores the broad definition of ‘availability to medicines’ from its regulatory authorisation, reimbursement, affordability, through to the physical stock availability component, covering some of the less explored topics to support greater understanding of the access issues in Europe, such examples include:

  • Purchasing power and medicines expenditure
  • International Reference Pricing (IRP)
  • Parallel trade within Europe
  • Shortages of innovative medicines
  • Company submissions
Contact Us